Spatiotemporal Control of Inflammatory Lytic Cell Death Through Optogenetic Induction of RIPK3 Oligomerization
- PMID: 38797430
- PMCID: PMC11234905
- DOI: 10.1016/j.jmb.2024.168628
Spatiotemporal Control of Inflammatory Lytic Cell Death Through Optogenetic Induction of RIPK3 Oligomerization
Abstract
Necroptosis is a programmed lytic cell death involving active cytokine production and plasma membrane rupture through distinct signaling cascades. However, it remains challenging to delineate this inflammatory cell death pathway at specific signaling nodes with spatiotemporal accuracy. To address this challenge, we developed an optogenetic system, termed Light-activatable Receptor-Interacting Protein Kinase 3 or La-RIPK3, to enable ligand-free, optical induction of RIPK3 oligomerization. La-RIPK3 activation dissects RIPK3-centric lytic cell death through the induction of RIPK3-containing necrosome, which mediates cytokine production and plasma membrane rupture. Bulk RNA-Seq analysis reveals that RIPK3 oligomerization results in partially overlapped gene expression compared to pharmacological induction of necroptosis. Additionally, La-RIPK3 activates separated groups of genes regulated by RIPK3 kinase-dependent and -independent processes. Using patterned light stimulation delivered by a spatial light modulator, we demonstrate precise spatiotemporal control of necroptosis in La-RIPK3-transduced HT-29 cells. Optogenetic control of proinflammatory lytic cell death could lead to the development of innovative experimental strategies to finetune the immune landscape for disease intervention.
Keywords: RIPK3; RNA-seq; lytic cell death; necroptosis; optogenetics.
Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Figures






Similar articles
-
Gene Delivery and Analysis of Optogenetic Induction of Lytic Cell Death.Curr Protoc. 2024 Apr;4(4):e1023. doi: 10.1002/cpz1.1023. Curr Protoc. 2024. PMID: 38606936 Free PMC article.
-
Human RIPK3 maintains MLKL in an inactive conformation prior to cell death by necroptosis.Nat Commun. 2021 Nov 22;12(1):6783. doi: 10.1038/s41467-021-27032-x. Nat Commun. 2021. PMID: 34811356 Free PMC article.
-
Casein kinase-1γ1 and 3 stimulate tumor necrosis factor-induced necroptosis through RIPK3.Cell Death Dis. 2019 Dec 4;10(12):923. doi: 10.1038/s41419-019-2146-4. Cell Death Dis. 2019. PMID: 31801942 Free PMC article.
-
Roles of RIPK3 in necroptosis, cell signaling, and disease.Exp Mol Med. 2022 Oct;54(10):1695-1704. doi: 10.1038/s12276-022-00868-z. Epub 2022 Oct 12. Exp Mol Med. 2022. PMID: 36224345 Free PMC article. Review.
-
Surviving death: emerging concepts of RIPK3 and MLKL ubiquitination in the regulation of necroptosis.FEBS J. 2023 Jan;290(1):37-54. doi: 10.1111/febs.16255. Epub 2021 Nov 16. FEBS J. 2023. PMID: 34710282 Review.
Cited by
-
Optogenetic engineering for precision cancer immunotherapy.Trends Pharmacol Sci. 2025 Jun 10:S0165-6147(25)00092-6. doi: 10.1016/j.tips.2025.05.002. Online ahead of print. Trends Pharmacol Sci. 2025. PMID: 40500674 Review.
-
Engineering sonogenetic EchoBack-CAR T cells.Cell. 2025 May 15;188(10):2621-2636.e20. doi: 10.1016/j.cell.2025.02.035. Epub 2025 Apr 2. Cell. 2025. PMID: 40179881
-
Optogenetically Activatable MLKL as a Standalone Functional Module for Necroptosis and Therapeutic Applications in Antitumoral Immunity.Adv Sci (Weinh). 2025 Apr;12(13):e2412393. doi: 10.1002/advs.202412393. Epub 2025 Feb 8. Adv Sci (Weinh). 2025. PMID: 39921454 Free PMC article.
-
Light-based technologies in immunotherapy: advances, mechanisms and applications.Immunotherapy. 2025 Feb;17(2):123-131. doi: 10.1080/1750743X.2025.2470111. Epub 2025 Mar 3. Immunotherapy. 2025. PMID: 40032620 Free PMC article. Review.
References
-
- Vanden Berghe T, Linkermann A, Jouan-Lanhouet S, Walczak H, Vandenabeele P. Regulated necrosis: the expanding network of non-apoptotic cell death pathways. Nat Rev Mol Cell Biol. 15 (2014) 135–147. - PubMed
-
- Degterev A, Huang Z, Boyce M, Li Y, Jagtap P, Mizushima N, et al. Chemical inhibitor of nonapoptotic cell death with therapeutic potential for ischemic brain injury. Nat Chem Biol. 1 (2005) 112–119. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Molecular Biology Databases
Miscellaneous